Participant number: 9
Legal Name: Toulouse University Hospital
Pr Alessandra Bura-Rivière
Description of the legal entity:
At the heart of the largest region of France, just under 3 million habitants and with one of the greatest rate of annual growth in Europe, the Centre Hospitalier Universitaire (CHU – University Hospital) of Toulouse is the referral facility in the region. It comprises more than 150 public and private institutions, located at several sites around the city. Toulouse University Hospital is the largest employer in the region, fulfilling its mission of care, prevention, education and research with nearly 3 500 doctors and 10 000 hospital staff. Organized around 15 clinical centers, it supports about 200 000 patients and 600 000 consultants each year, which ranks it in the second position in France among the French. CHU Toulouse coordinates national or is associated with eight reference centers for rare diseases and 33 competence centers. The quality of medical care and research of the CHU of Toulouse is making the tops of the chats of the French national press since more than 15 years.
The clinical service currently receives in consultation 6 to 10 patients per week. Patients will be recruited in the vascular medicine department of Prof Bura-Riviere, reference center for the follow-up of patients with lymphedema following breast cancer treatment.
The Research, development and Innovation direction
Research, development and innovation direction is constituted of 4 different departments to support research done by investigators at the CHUT. Within these departments’ legal unit will be in charge of management of intellectual property, innovation management, patents etc. The European project unit will manage administrative and financial aspects of SHIELDS projects. The regulatory unit in charge to obtain authorization from authorities and ethic comitee before starting clinical study.
Prof Alessandra BURA-RIVIERE (Female): Dr Bura-Rivière is the chief medical officer of the vascular medicine department, clinical professor of medicine at Toulouse University Medical Center, France. Dr. Bura-Riviere career has been dedicated to management of peripheral vascular diseases (thrombosis, peripheral arterial disease) and to the development of novel therapeutics aimed at the reversal or repair of chronic vascular conditions such as critical limb ischemia.
Dr Julie MALLOIZEL-DELAUNEY (Female): She is in charge of the lymphedema patients in the vascular medicine department of Toulouse hospital. Dr Malloizel-Delauney has an average consultation of 6 to 10 lymphedema patients per week. Dr Malloizel-Delauney has also a research activity in collaboration with Dr Garmy-Susini’s laboratory.
CHUT Main tasks in the project per WP
- WP7: CHUT is WP leader, sponsor of the clinical trial and will conduct the TheraLymph gene therapy PhaseI/II trial.
WP9 CHUT will contribute to dissemination and communication activities
List of up to 5 relevant publications, and/or products, services (including widely-used datasets or software), or other achievements relevant to the call content
Bura A, Planat-Benard V, Bourin P, Silvestre JS, Gross F, Grolleau JL, Saint-Lebese B, Peyrafitte JA, Fleury S, Gadelorge M, Taurand M, Dupuis-Coronas S, Leobon B, Casteilla L. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.
Cytotherapy. 2014 Feb;16(2):245-57.
Morfoisse F, Tatin F, Chaput B, Therville N, Vaysse C, Métivier R, Malloizel-Delaunay J, Pujol F, Godet AC, De Toni F, Boudou F, Grenier K, Dubuc D, Lacazette E, Prats AC, Guillermet-Guibert J, Lenfant F, Garmy-Susini B.LymphaticVasculature Requires Estrogen Receptor-α Signaling to Protect From Lymphedema.
Arterioscler Thromb Vasc Biol. 2018
Belgrado JP, Vandermeeren L, Vankerckhove S, Valsamis JB, Malloizel-Delaunay J, Moraine JJ, Liebens F. Near-Infrared Fluorescence Lymphatic Imaging to Reconsider Occlusion Pressure of Superficial Lymphatic Collectors in Upper Extremities of Healthy Volunteers. Lymphat Res Biol. 2016 Jun;14(2):70-7
Caradu C, Couffinhal T, Chapouly C, Guimbal S, Hollier PL, Ducasse E, Bura-Rivière A, Dubois M, Gadeau AP, Renault MA. Restoring Endothelial Function by Targeting Desert Hedgehog Downstream of Klf2 Improves Critical Limb Ischemia in Adults. Circ Res. 2018 Oct 12;123(9):1053-1065.
Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40.
List of up to 5 relevant previous projects or activities, connected to the subject of this proposal
Dr Malloizel Delauney and Bura-Riviere are actively involved in clinical trials focussing on vascular diseases:
Dr Malloizel Delauney:
Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment (Recruiting) ; condition : Lymphedema. Location : University Hospital of Toulouse, France.
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants (Recruiting) ; condition : Renal insufficiency. Location : University Hospital of Toulouse, France.
Allogenic adipose CELL derived regenerative angiogenic medicine in critical limb ischemia. Ongoing. Condition: peripheral arterial disease. Location: University Hospital of Toulouse, France.
Autologous dipose CELL Derived Regenerative Endothelial Angiogenic Medicine (National PHRC, completed) ; condition : Peripheral Vascular Diseases. Location : University Hospital of Toulouse, France.
Development and Validation of a Clinical Prediction Rule for Lower Limb Critical Limb Ischaemia (PREDICCMI) (recruiting) ; condition : Lower Limb Ischaemia. Location : University Hospital of Toulouse, France.
Infrastructure and/or major items of technical equipment
Describe any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work.
We are determined to find a treatment.